The scanner, which includes been manufactured by Philips Medical features and Systems a 5.5 tonne magnet, will be released by Professor Colin Blakemore, Chief Executive of the Medical Research Council and Professor Alan Gilbert, Vice and President Chancellor of The University of Manchester. Professor Colin Sibley, Associate Dean for Research in the University’s Faculty of Medical and Human Sciences said: This piece of equipment can help us to unravel some of the mysteries of the mind and how it operates. For the first time we are able to see how different parts of the brain communicate with one another and this will become invaluable to numerous different regions of our research. Related StoriesMeat-rich diet may increase kidney cancer riskStudy shows uncommon HER2 missense mutations do not spread breasts cancer on the ownOvarian cancer individuals with a brief history of oral contraceptive use have better outcomes The scanner will lead to improvements in diagnosing and treating major conditions such as stroke, malignancy and mental disease.Goldberg, W.R. Smith, and D. Buchwald.. Deepak L. Bhatt, M.D., M.P.H., Gregg W. Stone, M.D., Kenneth W. Mahaffey, M.D., C. Michael Gibson, M.D., P. Gabriel Steg, M.D., Christian W. Hamm, M.D., Matthew J. Price, M.D., Sergio Leonardi, M.D., Dianne Gallup, M.S., Ezio Bramucci, M.D., Peter W. Radke, M.D.D., D.Sc., Frantisek Tousek, M.D., Jeffrey Tauth, M.D., Douglas Spriggs, M.D., Brent T. McLaurin, M.D., Dominick J. Angiolillo, M.D., Ph.D.D., Tiepu Liu, M.D., Ph.D., Jayne Prats, Ph.D., Meredith Todd, B.Sc., Simona Skerjanec, Pharm.D., Harvey D. White, D.Sc., and Robert A. Harrington, M.D. For the CHAMPION PHOENIX Investigators: Aftereffect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events Percutaneous coronary intervention with stent implantation is certainly trusted to reduce the chance of death or myocardial infarction in individuals with acute coronary syndromes also to reduce the burden of angina and improve the standard of living in patients with stable angina.1-5 Despite advances in adjunctive pharmacotherapy, thrombotic complications during PCI remain a significant concern.6 Antiplatelet therapies, like the P2Y12-receptor inhibitors, decrease the threat of ischemic events, stent thrombosis particularly.7-10 To date, only oral P2Y12 inhibitors have been available.